Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
186.85
Nov 05 • 3:59 PM ET Dollar change-2.16 Percentage change(-1.14%)
Aftermarket Close
185.60
Aftermarket • 7:53 PM ET Dollar change-1.25 Percentage change(-0.67%)
Index
-
Market Cap
289.79B
Enterprise Value
315.90B
Income
11.03B
Sales
62.38B
Book/sh
33.36
Cash/sh
5.27
Employees
96100
IPO
Oct 17, 2003
P/E
26.44
Forward P/E
16.46
PEG
1.46
P/S
4.65
P/B
5.60
P/C
35.49
P/FCF
28.17
EV/EBITDA
15.08
EV/Sales
5.06
Quick Ratio
0.79
Current Ratio
1.01
Debt/Eq
0.66
LT Debt/Eq
0.56
Option/Short
Yes / Yes
EPS (ttm)
7.07
EPS next Y
11.35
EPS next Q
2.33
EPS this Y
12.04%
EPS next Y
10.62%
EPS next 5Y
11.24%
EPS past 3/5Y
45.90% 22.05%
Sales past 3/5Y
9.82% 16.31%
EPS Y/Y TTM
17.34%
Sales Y/Y TTM
7.32%
EPS Q/Q
23.13%
Sales Q/Q
6.70%
Insider Own
3.44%
Insider Trans
-0.02%
Inst Own
60.91%
Inst Trans
-0.89%
ROA
9.41%
ROE
22.60%
ROIC
13.70%
Gross Margin
74.11%
Oper. Margin
23.31%
Profit Margin
17.68%
SMA20
8.89%
SMA50
12.54%
SMA200
3.76%
Trades
Shs Outstand
1.55B
Shs Float
1.50B
52W High
212.71 -12.16%
52W Low
153.41 21.80%
Volatility
2.37% 1.96%
ATR (14)
4.59
RSI (14)
69.52
Beta
0.28
Rel Volume
1.51
Avg Volume
3.21M
Volume
4,842,579
Perf Week
7.14%
Perf Month
16.69%
Perf Quarter
15.75%
Perf Half Y
2.37%
Perf YTD
6.47%
Perf Year
13.06%
Perf 3Y
47.94%
Perf 5Y
48.92%
Perf 10Y
246.02%
Prev Close
189.01
Price
186.85
Change %
-1.14%
Consensus
Buy
Avg. Price Target
$228.13
Implied Upside
+22.1%
Analysts3incl. previous ratings
Rating Distribution1 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 15, 2026Upgrade
DB logoDDeutsche Bank
Sell → Hold
Sep 09, 2026Initiated
RY logoRRBC Capital Mkts
Outperform
Jul 13, 2026Downgrade
HSBC logoHHSBC Securities
Buy → Hold
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sharma ManiSee RemarksAug 08 '26Buy160.57203,24919,288Sep 11 04:05 PM
Sharma ManiSee RemarksMay 20 '26Sale185.7811,8932,209,48219,262May 22 04:05 PM
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.
M.B.A.Mr. Pascal Claude Roland Soriot D.V.M.
CFO & Executive DirectorDr. Aradhana Sarin M.D.
EVP of Global opt. & ITMs. Pam P. Cheng
Head of Investor RelationsMr. Joris Silon
CHROMr. Jeffrey Pott J.D.